We anticipate there will be continued high demand for influenza vaccines this year. We appreciate your continued support with vaccinating and protecting our communities.

Key Messages

  • General Practitioner and Nurse Practitioner Offices: Influenza vaccine orders will be submitted using the online vaccine order request form. We will advise you next week, when you can start submitting your orders.
  • Pharmacists will continue to request their vaccine through the BC Pharmacy Association/Distributors.
  • Long Term Care and Assisted Living Facilities:
    • Please reach out to your local public health unit or your acute care pharmacy partner from whom you received the influenza vaccine last year.
  • Co-administration of influenza and COVID-19 vaccines is safe and effective.
  • Invites for the fall COVID-19 booster have begun. All Fraser Health clinics and participating pharmacies, will have the COVID-19 Moderna bivalent vaccine available for eligible clients.

Vaccine Eligibility and Intended Use

Table 1: 2022/2023 Influenza Vaccine Eligibility and Intended Use
Age Group Preferred Vaccine Comments
6-23 months Fluzone®  
2-17 years



Flumist® Quadrivalent is contraindicated for those with severe asthma or active wheezing (on high dose inhaled or oral steroids or medically attended wheezing in the past 7 days).
18 years and older Fluzone® Flumist® may be offered to those 18-59 years of age who have needle phobia and are unwilling to get another influenza vaccine, provided informed consent includes that Quadrivalent Inactivated Influenza Vaccine provides better protection against influenza for this age group.
65 years and older Fluad® If Fluad® is unavailable Fluzone® should be given.
65 years and older who are residents of Long-Term care and Assisted Living facilities or First Nations Communities Fluzone® High-Dose If Fluzone® High-Dose is unavailable Fluad® should be used.
If neither of these products are available, Fluzone® may be used.

Vaccine products, format and expiry

Because influenza viruses change often (mutate), the specific virus strains in the vaccine are reviewed each year by the World Health Organization and updated as needed so that there is the greatest probability of matching the virus strains that are circulating in the community. The 2022-2023 influenza vaccines contain the following strains:

  • A/Victoria/2570/2019 (H1N1)pdm09-like virus
  • A/Darwin/9/2021 (H3N2)-like virus (new this year)
  • B/Austria/1359417/2021-like virus (new this year)
  • B/Phuket/3073/2013-like virus (in quadrivalent vaccines only)
Table 2: 2022/2023 Influenza Vaccines

Fluzone® Quadrivalent

Inactivated, Trivalent
Flumist® Quadrivalent
Live Attenuated
Fluzone® High-Dose Quadrivalent
Supplier Sanofi Pasteur Seqirus AstraZeneca Sanofi Pasteur
Indicated age group 6 months and older 65 years and older

 2-17 years old inclusive

18-59 years old with needle phobia (refer to Table 1)

65 years & older who are residents of Long-Term Care and Assisted Living facilities or First Nations communities
Formats available Multi-dose vial and pre-filled syringe Pre-filled syringe Intranasal spray Pre-filled syringe
Expiry Use up to the date of expiry listed on the vial or pre-filled syringe Use up to the date of expiry listed on the pre-filled syringe

Use up to the date of expiry listed on the sprayer/box

Shelf life is approx. 4 months

Use up to the date of expiry listed on the pre-filled syringe
Contains thimerosal

Yes in multi-dose vial

No in pre-filled syringe

 No No No
Vaccines should be kept at 2-8°C at all times. See this quick reference on storage and handling

Additional resources

comments powered by Disqus